These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 24859689

  • 21. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 22. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 23. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A, Wood K, Salgia R.
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [Abstract] [Full Text] [Related]

  • 24. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [Abstract] [Full Text] [Related]

  • 25. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M, Wynes MW, Hirsch FR.
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [Abstract] [Full Text] [Related]

  • 26. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, Borget I, Planchard D, Taylor M, André F, Soria JC, Vielh P, Besse B, Farace F.
    J Clin Oncol; 2013 Jun 20; 31(18):2273-81. PubMed ID: 23669222
    [Abstract] [Full Text] [Related]

  • 27. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul 20; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 28. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C, Spitaleri G, Catania C, Barberis M, Noberasco C, Santarpia M, Delmonte A, Toffalorio F, Conforti F, De Pas TM.
    Crit Rev Oncol Hematol; 2014 Mar 20; 89(3):358-65. PubMed ID: 24156959
    [Abstract] [Full Text] [Related]

  • 29. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 20; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 30. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 20; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 31. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
    Sasaki T, Jänne PA.
    Clin Cancer Res; 2011 Dec 01; 17(23):7213-8. PubMed ID: 22010214
    [Abstract] [Full Text] [Related]

  • 32. Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.
    Pennell NA.
    Am J Manag Care; 2012 May 01; 18(5 Spec No. 2):SP84-7. PubMed ID: 22693986
    [No Abstract] [Full Text] [Related]

  • 33. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
    Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, Chen HJ, Xie Z, Su J, Han JF, Wu YL.
    Clin Lung Cancer; 2016 May 01; 17(3):223-31. PubMed ID: 26454342
    [Abstract] [Full Text] [Related]

  • 34. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM, Bepler G.
    Future Oncol; 2011 Aug 01; 7(8):947-53. PubMed ID: 21823889
    [Abstract] [Full Text] [Related]

  • 35. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.
    Genomics; 2013 Sep 01; 102(3):157-62. PubMed ID: 23434628
    [Abstract] [Full Text] [Related]

  • 36. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 37. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C.
    Clin Lung Cancer; 2015 Mar 01; 16(2):86-91. PubMed ID: 25458559
    [Abstract] [Full Text] [Related]

  • 38. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH.
    Expert Rev Anticancer Ther; 2012 Feb 01; 12(2):151-62. PubMed ID: 22316363
    [Abstract] [Full Text] [Related]

  • 39. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 40. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.
    Target Oncol; 2013 Mar 27; 8(1):55-67. PubMed ID: 23325296
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.